Pharmacotherapeutic group: venopharmaceutical, antivaricose agent
ATC code: C05BX01
Calcium dobesilate acts on capillary walls by correcting their impaired physiological functions – increased permeability and decreased resistance. It increases erythrocyte flexibility, inhibits platelet aggregation, and in diabetic retinopathy reduces plasma and blood viscosity with subsequent improvement of rheological properties of blood and tissue perfusion. These properties help correct capillary dysfunctions, both functional and those caused by congenital or acquired metabolic disorders. Calcium dobesilate also helps reduce oedema.
⚠️ Warnings
In cases of severe renal insufficiency requiring dialysis, the dosage may be reduced.
In very rare cases, administration of calcium dobesilate may cause agranulocytosis (see section 4.8).
In such cases, symptoms may appear such as high fever, oral infections (tonsillitis), sore throat, anogenital inflammation, and other symptoms that are common signs of infection. If any of these symptoms occur, treatment must be discontinued. It is then essential to immediately check the blood count and leukocyte differential.
Doxium 500 may induce severe hypersensitivity reactions (anaphylactic reaction or shock). In cases of hypersensitivity reactions, treatment must be discontinued.
Elderly patients
In clinical studies with calcium dobesilate, the elderly population was widely represented and no overall safety concerns emerged.
Paediatric population
No studies investigating the use of calcium dobesilate in the paediatric population have been conducted.
